DOP2016000270A - Inhibidores espirocíclicos sustituidos de la autotaxina y su preparación y uso en el tratamiento de enfermedades dependientes o mediadas por lpa - Google Patents
Inhibidores espirocíclicos sustituidos de la autotaxina y su preparación y uso en el tratamiento de enfermedades dependientes o mediadas por lpaInfo
- Publication number
- DOP2016000270A DOP2016000270A DO2016000270A DO2016000270A DOP2016000270A DO P2016000270 A DOP2016000270 A DO P2016000270A DO 2016000270 A DO2016000270 A DO 2016000270A DO 2016000270 A DO2016000270 A DO 2016000270A DO P2016000270 A DOP2016000270 A DO P2016000270A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- mediated
- treatment
- autotaxin
- lpa
- replaced
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461975123P | 2014-04-04 | 2014-04-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2016000270A true DOP2016000270A (es) | 2016-12-15 |
Family
ID=54241341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2016000270A DOP2016000270A (es) | 2014-04-04 | 2016-10-03 | Inhibidores espirocíclicos sustituidos de la autotaxina y su preparación y uso en el tratamiento de enfermedades dependientes o mediadas por lpa |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10011601B2 (enExample) |
| EP (1) | EP3125895A4 (enExample) |
| JP (2) | JP6616821B2 (enExample) |
| KR (1) | KR20160133004A (enExample) |
| CN (1) | CN107106559A (enExample) |
| AP (1) | AP2016009496A0 (enExample) |
| AU (2) | AU2015240519B2 (enExample) |
| CA (1) | CA2943874A1 (enExample) |
| CL (1) | CL2016002516A1 (enExample) |
| CR (1) | CR20160496A (enExample) |
| CU (1) | CU24442B1 (enExample) |
| DO (1) | DOP2016000270A (enExample) |
| EA (1) | EA201691840A1 (enExample) |
| EC (1) | ECSP16084293A (enExample) |
| IL (1) | IL248050A0 (enExample) |
| MD (1) | MD20160116A2 (enExample) |
| MX (1) | MX2016013049A (enExample) |
| PE (1) | PE20170206A1 (enExample) |
| PH (1) | PH12016501922A1 (enExample) |
| SG (1) | SG11201607920RA (enExample) |
| WO (1) | WO2015154023A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2861566T (pt) | 2012-06-13 | 2017-02-08 | Hoffmann La Roche | Novos diazaspirocicloalcanos e azaspirocicloalcanos |
| AU2013322838B2 (en) | 2012-09-25 | 2018-02-01 | F. Hoffmann-La Roche Ag | New bicyclic derivatives |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| AU2014356583B2 (en) | 2013-11-26 | 2019-02-28 | F. Hoffmann-La Roche Ag | New octahydro-cyclobuta (1,2-c;3,4-c')dipyrrol-2-yl |
| AU2015238537B2 (en) | 2014-03-26 | 2019-08-01 | F. Hoffmann-La Roche Ag | Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors |
| WO2015144609A1 (en) | 2014-03-26 | 2015-10-01 | F. Hoffmann-La Roche Ag | Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors |
| CR20160496A (es) | 2014-04-04 | 2017-01-02 | X-Rx Inc | Inhibidores espirocíclicos sustituidos de la autotaxina |
| MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| UA123362C2 (uk) | 2015-09-04 | 2021-03-24 | Ф. Хоффманн-Ля Рош Аг | Феноксиметильні похідні |
| CR20180057A (es) | 2015-09-24 | 2018-04-02 | Hoffmann La Roche | Nuevos compuestos biciclicos como inhibidores duales de atx/ca. |
| AU2016328535A1 (en) | 2015-09-24 | 2017-11-09 | F. Hoffmann-La Roche Ag | Bicyclic compounds as ATX inhibitors |
| KR20180053408A (ko) | 2015-09-24 | 2018-05-21 | 에프. 호프만-라 로슈 아게 | 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서의 신규한 이환형 화합물 |
| CR20180072A (es) | 2015-09-24 | 2018-02-26 | Hoffmann La Roche | Nuevos compuestos biciclicos como inhibidores de atx |
| CA3016081A1 (en) | 2016-03-04 | 2017-09-08 | Gilead Sciences, Inc. | Compositions and combinations of autotaxin inhibitors |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| CN108456208B (zh) * | 2017-02-22 | 2021-04-16 | 广州市恒诺康医药科技有限公司 | 氮杂螺环类化合物及其制备方法和应用 |
| CN110382484B (zh) | 2017-03-16 | 2022-12-06 | 豪夫迈·罗氏有限公司 | 新的作为atx抑制剂的二环化合物 |
| SG11201908560SA (en) | 2017-03-16 | 2019-10-30 | Hoffmann La Roche | Heterocyclic compounds useful as dual atx/ca inhibitors |
| KR101798840B1 (ko) | 2017-05-17 | 2017-11-17 | 주식회사 레고켐 바이오사이언스 | 신규 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물 |
| US10961242B2 (en) | 2017-05-17 | 2021-03-30 | Legochem Biosciences, Inc. | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same |
| CA3076477A1 (en) | 2017-09-29 | 2019-04-04 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2020051230A1 (en) * | 2018-09-04 | 2020-03-12 | X-Rx, Inc. | Amorphous pharmaceutical compositions and uses thereof |
| US12383547B2 (en) | 2020-07-01 | 2025-08-12 | Vanderbilt University | Methods of treatment for a kidney disease |
| KR20230051227A (ko) * | 2020-08-14 | 2023-04-17 | 노파르티스 아게 | 헤테로아릴 치환된 스피로피페리디닐 유도체 및 이의 제약 용도 |
| US11434222B2 (en) | 2020-11-13 | 2022-09-06 | H. Lundbeck A/S | MAGL inhibitors |
| CN112675308B (zh) * | 2020-12-09 | 2023-05-05 | 中国人民解放军军事科学院军事医学研究院 | 抑制enpp2基因和/或蛋白表达的物质在制备治疗多发性骨髓瘤的药物中的应用 |
| WO2022149010A1 (en) * | 2021-01-05 | 2022-07-14 | Cadila Healthcare Limited | Novel inhibitors of autotaxin |
| CN119137114A (zh) | 2022-05-04 | 2024-12-13 | H.隆德贝克有限公司 | 作为单酰基甘油脂肪酶抑制剂的(s)-1-(哒嗪-3-基氨基甲酰基)-6-氮杂螺[2.5]辛烷-6-甲酸1,1,1,3,3,3-六氟丙-2-酯的结晶形式 |
| WO2024073658A1 (en) * | 2022-09-30 | 2024-04-04 | Genentech, Inc. | Hydantoin modulators of cholesterol biosynthesis and their use for promoting remyelination |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5877182A (en) | 1996-09-13 | 1999-03-02 | Merck & Co., Inc. | Piperidines promote release of growth hormone |
| HUP0001285A3 (en) | 1997-05-08 | 2000-10-30 | Smithkline Beecham Corp Philap | Pyrrolidine derivatives as protease inhibitors, process for producing them and pharmaceutical compositions containing them |
| GB0030303D0 (en) | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
| HUP0600103A2 (en) * | 2001-03-02 | 2006-06-28 | Bristol Myers Squibb Co | Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders |
| JP2005511475A (ja) * | 2001-03-02 | 2005-04-28 | ブリストル−マイヤーズ スクイブ カンパニー | メラノコルチン受容体のモジュレーターとして有用な化合物及びそれを含む製薬組成物 |
| AR036663A1 (es) * | 2001-10-01 | 2004-09-22 | Bristol Myers Squibb Co | Compuestos de espiro-hidantoina utiles como agentes anti-inflamatorios, las composiciones farmaceuticas que las contienen y los intermediarios para preparar dichos compuestos |
| US20040192674A1 (en) | 2003-02-14 | 2004-09-30 | Marquis Robert W. | Cathepsin L inhibitors |
| CA2512886A1 (en) | 2003-02-28 | 2004-09-10 | Galderma Research & Development, S.N.C. | Ligands that modulate lxr-type receptors |
| WO2005122379A2 (en) * | 2004-05-27 | 2005-12-22 | The Regents Of The University Of California | Alpha-4 beta-1 integrin ligands for imaging and therapy |
| WO2006137465A1 (ja) | 2005-06-24 | 2006-12-28 | Shionogi & Co., Ltd. | 含窒素複素環誘導体 |
| US7601844B2 (en) | 2006-01-27 | 2009-10-13 | Bristol-Myers Squibb Company | Piperidinyl derivatives as modulators of chemokine receptor activity |
| US8329159B2 (en) * | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8906859B2 (en) * | 2006-11-10 | 2014-12-09 | Cera Therapeutics, Inc. | Uses of kappa opioid synthetic peptide amides |
| CN101534824A (zh) | 2006-11-17 | 2009-09-16 | 艾博特公司 | 作为化学活素受体拮抗剂的氨基吡咯烷 |
| US8378100B2 (en) | 2008-01-09 | 2013-02-19 | University Of Virginia Patent Foundation | Phosphonate derivatives as autotaxin inhibitors |
| EP2268143A4 (en) | 2008-03-20 | 2012-06-27 | Forest Lab Holdings Ltd | NEW PIPERIDINE DERIVATIVES AS INHIBITORS OF THE STEAROYL COA DESATURASE |
| US20110110886A1 (en) | 2008-06-13 | 2011-05-12 | Yale University | Small molecule inhibitors of autotaxin and methods of use |
| WO2010037081A1 (en) | 2008-09-29 | 2010-04-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific spiro-piperidine compounds |
| SG171809A1 (en) | 2008-12-01 | 2011-07-28 | Merck Patent Gmbh | 2, 5-diamino-substituted pyrido [4, 3-d] pyrimidines as autotaxin inhibitors against cancer |
| ES2547124T3 (es) | 2009-04-02 | 2015-10-01 | Merck Patent Gmbh | Inhibidores de autotaxina |
| JP5767205B2 (ja) | 2009-04-02 | 2015-08-19 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | オートタキシン阻害剤としての複素環式化合物 |
| MX2011010203A (es) | 2009-04-02 | 2011-10-14 | Merck Patent Gmbh | Derivados de piperidina y piperazina como inhibidores de autotaxina. |
| DK2368890T3 (da) * | 2009-06-11 | 2013-07-22 | Abbvie Bahamas Ltd | Hepatitis C-virusinhibitorer |
| DE102009033392A1 (de) | 2009-07-16 | 2011-01-20 | Merck Patent Gmbh | Heterocyclische Verbindungen als Autotaxin-Inhibitoren II |
| WO2011017350A2 (en) | 2009-08-04 | 2011-02-10 | Amira Pharmaceuticals, Inc. | Compounds as lysophosphatidic acid receptor antagonists |
| KR101184115B1 (ko) * | 2009-08-31 | 2012-09-18 | 일동제약주식회사 | 신규 펩티드 데포르밀라제 저해제 화합물 및 그 제조방법 |
| US8497371B2 (en) | 2009-10-26 | 2013-07-30 | University Of Memphis Research Foundation | Pipemidic acid derivative autotaxin inhibitors |
| US8518945B2 (en) | 2010-03-22 | 2013-08-27 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
| EP2552914B1 (de) | 2010-03-26 | 2015-11-11 | Merck Patent GmbH | Benzonaphthyridinamine als autotaxin-inhibitoren |
| JP2011219368A (ja) | 2010-04-02 | 2011-11-04 | Daiichi Sankyo Co Ltd | Ｎ−サリチルアミノ酸誘導体 |
| JP2013536200A (ja) | 2010-08-20 | 2013-09-19 | アミラ ファーマシューティカルス，インコーポレーテッド | オートタキシン阻害剤およびその使用 |
| EP2714680B1 (en) | 2011-05-27 | 2015-11-25 | Amira Pharmaceuticals, Inc. | Heterocyclic autotaxin inhibitors and uses thereof |
| UY34094A (es) * | 2011-05-27 | 2013-01-03 | Novartis Ag | Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina |
| EP2771325B1 (en) | 2011-10-28 | 2017-06-28 | Inhibitaxin Limited | Pyridazine derivatives useful in therapy |
| PT2861566T (pt) * | 2012-06-13 | 2017-02-08 | Hoffmann La Roche | Novos diazaspirocicloalcanos e azaspirocicloalcanos |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| TW201500356A (zh) | 2013-04-12 | 2015-01-01 | Lilly Co Eli | 二氫吡啶并嘧啶化合物 |
| SG11201600241RA (en) | 2013-07-18 | 2016-02-26 | Novartis Ag | Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core |
| EP3022201A1 (en) | 2013-07-18 | 2016-05-25 | Novartis AG | Autotaxin inhibitors |
| US9951026B2 (en) | 2013-09-17 | 2018-04-24 | Pharmakea, Inc. | Heterocyclic vinyl autotaxin inhibitor compounds |
| WO2015042053A1 (en) | 2013-09-17 | 2015-03-26 | Pharmakea, Inc. | Vinyl autotaxin inhibitor compounds |
| US9850203B2 (en) | 2013-09-26 | 2017-12-26 | Pharmakea, Inc. | Autotaxin inhibitor compounds |
| CR20160496A (es) | 2014-04-04 | 2017-01-02 | X-Rx Inc | Inhibidores espirocíclicos sustituidos de la autotaxina |
| JP6592008B2 (ja) | 2014-04-23 | 2019-10-16 | エックス−アールエックス， インコーポレイテッド | オートタキシンの置換ｎ−（２−アミノ）−２−オキソエチルベンズアミド阻害剤およびそれらの調製、ならびにｌｐａ依存性またはｌｐａ媒介性疾患の処置における使用 |
-
2015
- 2015-04-03 CR CR20160496A patent/CR20160496A/es unknown
- 2015-04-03 MD MDA20160116A patent/MD20160116A2/ro not_active Application Discontinuation
- 2015-04-03 EA EA201691840A patent/EA201691840A1/ru unknown
- 2015-04-03 SG SG11201607920RA patent/SG11201607920RA/en unknown
- 2015-04-03 AU AU2015240519A patent/AU2015240519B2/en not_active Ceased
- 2015-04-03 AP AP2016009496A patent/AP2016009496A0/en unknown
- 2015-04-03 US US15/300,762 patent/US10011601B2/en not_active Expired - Fee Related
- 2015-04-03 CA CA2943874A patent/CA2943874A1/en not_active Abandoned
- 2015-04-03 EP EP15773254.6A patent/EP3125895A4/en not_active Withdrawn
- 2015-04-03 JP JP2017503794A patent/JP6616821B2/ja not_active Expired - Fee Related
- 2015-04-03 CU CU2016000150A patent/CU24442B1/es unknown
- 2015-04-03 PE PE2016001885A patent/PE20170206A1/es unknown
- 2015-04-03 MX MX2016013049A patent/MX2016013049A/es unknown
- 2015-04-03 KR KR1020167030589A patent/KR20160133004A/ko not_active Withdrawn
- 2015-04-03 CN CN201580028170.3A patent/CN107106559A/zh active Pending
- 2015-04-03 WO PCT/US2015/024338 patent/WO2015154023A1/en not_active Ceased
-
2016
- 2016-09-26 IL IL248050A patent/IL248050A0/en unknown
- 2016-09-28 PH PH12016501922A patent/PH12016501922A1/en unknown
- 2016-10-03 DO DO2016000270A patent/DOP2016000270A/es unknown
- 2016-10-04 CL CL2016002516A patent/CL2016002516A1/es unknown
- 2016-10-26 EC ECIEPI201684293A patent/ECSP16084293A/es unknown
-
2018
- 2018-02-14 US US15/896,905 patent/US10233182B2/en not_active Expired - Fee Related
-
2019
- 2019-04-12 US US16/256,429 patent/US20190225611A1/en not_active Abandoned
- 2019-11-08 JP JP2019203023A patent/JP2020040960A/ja active Pending
- 2019-11-15 AU AU2019264641A patent/AU2019264641A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN107106559A (zh) | 2017-08-29 |
| AU2019264641A1 (en) | 2019-12-05 |
| AU2015240519A1 (en) | 2016-10-20 |
| SG11201607920RA (en) | 2016-10-28 |
| ECSP16084293A (es) | 2017-01-31 |
| MD20160116A2 (ro) | 2017-04-30 |
| JP2020040960A (ja) | 2020-03-19 |
| US10011601B2 (en) | 2018-07-03 |
| US20180282332A1 (en) | 2018-10-04 |
| CL2016002516A1 (es) | 2017-05-12 |
| PH12016501922A1 (en) | 2016-12-19 |
| CU24442B1 (es) | 2019-09-04 |
| AP2016009496A0 (en) | 2016-10-31 |
| US10233182B2 (en) | 2019-03-19 |
| KR20160133004A (ko) | 2016-11-21 |
| EA201691840A1 (ru) | 2017-03-31 |
| JP2017513932A (ja) | 2017-06-01 |
| US20190225611A1 (en) | 2019-07-25 |
| CR20160496A (es) | 2017-01-02 |
| CA2943874A1 (en) | 2015-10-08 |
| EP3125895A4 (en) | 2017-08-30 |
| WO2015154023A1 (en) | 2015-10-08 |
| MX2016013049A (es) | 2017-04-27 |
| EP3125895A1 (en) | 2017-02-08 |
| JP6616821B2 (ja) | 2019-12-04 |
| AU2015240519B2 (en) | 2019-08-15 |
| PE20170206A1 (es) | 2017-04-09 |
| CU20160150A7 (es) | 2017-02-02 |
| IL248050A0 (en) | 2016-11-30 |
| US20170166568A1 (en) | 2017-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2016000270A (es) | Inhibidores espirocíclicos sustituidos de la autotaxina y su preparación y uso en el tratamiento de enfermedades dependientes o mediadas por lpa | |
| CY1121413T1 (el) | Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα | |
| CR20160523A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| MX386935B (es) | Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades. | |
| CU20160188A7 (es) | Compuestos de indazole substituidos como inhibidores de irak4 | |
| MX388170B (es) | Polimorfos de selinexor | |
| BR112017006305A2 (pt) | compostos heteroarila como inibidores de btk e usos dos mesmos | |
| DOP2015000158A (es) | Inhibidores de prmt5 y sus usos | |
| CR20160456A (es) | Compuestos de heteroarilo o arilo bibíclicos fusionados | |
| EA201692176A1 (ru) | Полифторзамещенное соединение в качестве ингибитора тирозинкиназы брутона (btk) | |
| MX385332B (es) | Moduladores de ror-gamma. | |
| CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
| MX2017001279A (es) | Usos y composiciones de la flagelina. | |
| EA201791293A1 (ru) | Сайт-специфическое дозирование ингибитора btk | |
| MX382261B (es) | Derivados heterociclicos y uso de los mismos. | |
| MX376122B (es) | Composiciones de plinabulina. | |
| BR112017000456A2 (pt) | composições antivirais tópicas e métodos de uso das mesmas | |
| GT201500235A (es) | Estra -1,3,5 (10) , 16- tetraeno -3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1c3) | |
| UY36145A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| EA201791807A1 (ru) | Новый тритерпенон по с-3 с обратными амидными производными по с-17 в качестве ингибиторов вич | |
| UA120927C2 (uk) | Тритерпеноїди, заміщені в положенні 3 неароматичним кільцем, яке несе галогеналкільний замісник, з інгібуючою активністю щодо дозрівання віл | |
| BR112017013286A2 (pt) | composto de isoxazolina, e, uso de um composto de isoxazolina. | |
| MX2019003310A (es) | Inhibidores de dopamina-b-hidroxilasa. | |
| ECSP19013196A (es) | Derivado de triazolopirazinona útil como un inhibidor de pde1 humana | |
| JOP20200030A1 (ar) | مركب خماسي الحلقة |